share_log

Ladenburg Thalmann Initiates Coverage On Sonnet BioTherapeutics With Buy Rating, Announces Price Target of $7

Ladenburg Thalmann Initiates Coverage On Sonnet BioTherapeutics With Buy Rating, Announces Price Target of $7

拉登堡·塔尔曼以买入评级启动对Sonnet BioTherapeutics的报道,宣布目标股价为7美元
Benzinga ·  2023/11/27 09:00

Ladenburg Thalmann analyst Ahu Demir initiates coverage on Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy rating and announces Price Target of $7.

拉登堡·塔尔曼分析师阿胡·德米尔以买入评级开始对Sonnet BioTherapeutics(纳斯达克股票代码:SONN)进行报道,并宣布目标股价为7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发